🔗 Share this article

Given that the US continues making unprecedented changes to its vaccination guidelines, a particular individual appears somewhat surprisingly: Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by casting doubt on coronavirus vaccinations during the pandemic and has focused upon alleged fatalities after COVID-19 vaccination in her brief position at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Immunization Program

Agency leaders had intended to reveal radical revisions to the childhood immunization program recently, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would put the US out of step with many the international standard with no evidence for benefit. This reveal has been pushed back until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

A New Direction at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and vaccine branches as Høeg and Dr. Prasad solidify control at the FDA – and it points to a renewed priority upon dismantling already-approved immunizations at the FDA.

Høeg has frequently advocated for halting some pediatric shot schedules in the US to become more in line with the Danish model, a nation with universal health coverage and a population approximately the size of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Expertise

Høeg has no apparent experience in drug development, regulation or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, remarked Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a large organization. She lacks background in industry regulation.”

Former commissioners of the center would “understand regulatory frameworks and the research of drug development”, commented Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who headed CBER have had.”

The drug center has an vast workload at the agency, she stated.

“Many people just focuses on the new drug program, but the generic drug division authorizes numerous generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those need to be managed,” Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to cause problems.”

There is also, a substantial management element to the position, which manages over 5,000 employees. “It is a enormous leadership role, if you perform it correctly,” the former official concluded.

Agency Reaction and Disputed Initiatives

Regarding concerns about Dr. Høeg's credentials and whether this assignment signifies more teamwork among FDA leaders on vaccines, a spokesperson responded that the “inquiries are based on inaccurate presumptions”.

“Her experience matches the duties of her job,” the official said, noting the period Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg takes over the agency head's controversial priority voucher program, a disputed rapid drug-approval program that allegedly worried her former heads. “By what process are these therapies being selected for this voucher program? Who is making the decisions?” Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the FDA seems to be moving towards laxer oversight of most medications, with the exception of immunizations.”

Documented History on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, track record, some experts observe. She released a research paper using non-validated public submissions to estimate the incidence of heart inflammation after COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccinations are more dangerous than they are.

Among her “desired changes” for the current administration encompassed changing rules for new vaccines and ending “optional” immunizations, she remarked following the vote on a audio program. At the FDA, Høeg has allegedly suggested preventing young men from receiving COVID-19 vaccines.

“She is an complete dogmatist who begins with her conclusions and works backwards to accommodate the science in a extremely deceptive, fraudulent manner,” Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|